{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:43:39Z","timestamp":1788403419230,"version":"build-2803163510"},"reference-count":126,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["12\/01\/52"],"award-info":[{"award-number":["12\/01\/52"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"Background<\/jats:title>\nChronic kidney disease affects around 10% of the global population and is associated with significant risk of progression to end-stage renal disease and vascular events. Aldosterone receptor antagonists such as spironolactone have shown prognostic benefits in patients with heart failure, but effects on patients with chronic kidney disease are uncertain.<\/jats:p>\n<\/jats:sec>\nObjectives<\/jats:title>\nTo determine the effect of low-dose spironolactone on mortality and cardiovascular outcomes in people with chronic kidney disease stage 3b.<\/jats:p>\n<\/jats:sec>\nDesign<\/jats:title>\nProspective randomised open blinded end-point trial.<\/jats:p>\n<\/jats:sec>\nSettings<\/jats:title>\nThree hundred and twenty-nine general practitioner practices throughout the United Kingdom.<\/jats:p>\n<\/jats:sec>\nParticipants<\/jats:title>\nPatients meeting the criteria for chronic kidney disease stage 3b (estimated glomerular filtration rate 30\u201344\u00a0ml\/minute\/1.73\u00a0m2<\/jats:sup>) according to National Institute for Health and Care Excellence guidelines were recruited. Due to the higher than anticipated measurement error\/fluctuations, the eligible range was extended to 30\u201350\u00a0ml\/minute\/1.73\u00a0m2<\/jats:sup> following the initial recruitment period.<\/jats:p>\n<\/jats:sec>\nIntervention<\/jats:title>\nParticipants were randomised 1\u00a0:\u00a01 to receive either spironolactone 25\u00a0mg once daily in addition to standard care, or standard care only.<\/jats:p>\n<\/jats:sec>\nOutcome measures<\/jats:title>\nPrimary outcome was the first occurring of all-cause mortality, first hospitalisation for heart disease (coronary heart disease, arrhythmia, atrial fibrillation, sudden death, failed sudden death), stroke, heart failure, transient ischaemic attack or peripheral arterial disease, or first occurrence of any condition not listed at baseline. Secondary outcome measures included changes in blood pressure, renal function, B-type natriuretic peptide, incidence of hyperkalaemia and treatment costs and benefits.<\/jats:p>\n<\/jats:sec>\nResults<\/jats:title>\nOne thousand four hundred and thirty-four participants were randomised of the 3022 planned. We found no evidence of differences between the intervention and control groups in terms of effectiveness with the primary combined vascular end points, nor with the secondary clinical outcomes, including progression in renal decline. These results were similar for the total treatment periods or a 3-year follow-up period as originally planned. More adverse events were experienced and more participants discontinued treatment in the intervention group. Two-thirds of participants randomised to spironolactone stopped treatment within six months because they met pre-specified safety stop criteria. The addition of low-dose spironolactone was estimated to have a cost per quality-adjusted life-year gained value above the National Institute for Health and Care Excellence\u2019s threshold of \u00a330,000.<\/jats:p>\n<\/jats:sec>\nLimitations<\/jats:title>\nMain limitations were difficulties in recruiting eligible participants resulting in an underpowered trial with poor ethnic diversity taking twice as long as planned to complete. We have explored the data in secondary analyses that indicate that, despite these difficulties, the findings were reliable.<\/jats:p>\n<\/jats:sec>\nConclusions<\/jats:title>\nThe benefits of aldosterone receptor antagonism in chronic kidney disease trial found no evidence to support adding low-dose spironolactone (25\u00a0mg daily) in patients with chronic kidney disease stage 3b: there were no changes to cardiovascular events during the trial follow-up, either for the combined primary or individual components. There was also no evidence of benefit observed in rates of renal function decline over the trial, but much higher initial creatinine rise and estimated glomerular filtration rate decline, and to a higher percentage rate, in the intervention arm in the first few weeks of spironolactone treatment, which resulted in a high proportion of participants discontinuing spironolactone treatment at an early stage. These higher rates of negative renal change reduced in scale over the study but did not equalise between arms. The addition of 25\u00a0mg of spironolactone therefore provided no reno- or cardio-protection and was associated with an increase in adverse events.<\/jats:p>\n<\/jats:sec>\nFuture work<\/jats:title>\nThese findings might not be applicable to different mineralocorticoid receptor antagonists.<\/jats:p>\n<\/jats:sec>\nStudy registration<\/jats:title>\nCurrent Controlled Trials ISRCTN44522369.<\/jats:p>\n<\/jats:sec>\nFunding<\/jats:title>\nThis award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 12\/01\/52) and is published in full in Health Technology Assessment<\/jats:italic>; Vol. 29, No. 5. See the NIHR Funding and Awards website for further award information.<\/jats:p>\n<\/jats:sec>","DOI":"10.3310\/pyft6977","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T17:17:22Z","timestamp":1742404642000},"page":"1-130","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Benefits of aldosterone receptor antagonism in chronic kidney disease: the BARACK-D RCT"],"prefix":"10.3310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7976-7172","authenticated-orcid":true,"given":"F D Richard","family":"Hobbs","sequence":"first","affiliation":[{"name":"Nuffield Department of Primary Health Care Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3638-028X","authenticated-orcid":true,"given":"Richard","family":"McManus","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Health Care Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8926-2581","authenticated-orcid":true,"given":"Clare","family":"Taylor","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Health Care Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0352-3785","authenticated-orcid":true,"given":"Nicholas","family":"Jones","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Health Care Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0512-5062","authenticated-orcid":true,"given":"Joy","family":"Rahman","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Health Care Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7493-1850","authenticated-orcid":true,"given":"Jane","family":"Wolstenholme","sequence":"additional","affiliation":[{"name":"Nuffield Department of Population Health, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0519-2334","authenticated-orcid":true,"given":"Louise","family":"Jones","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Health Care Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8416-2159","authenticated-orcid":true,"given":"Jennifer","family":"Hirst","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Health Care Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6332-4641","authenticated-orcid":true,"given":"Sam","family":"Mort","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Health Care Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0331-7364","authenticated-orcid":true,"given":"Ly-Mee","family":"Yu","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Health Care Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2025,3]]},"reference":[{"key":"key2025031922413200_ref1-bib1","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/archinte.164.6.659","article-title":"Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization","volume":"164","author":"Keith","year":"2004","journal-title":"Arch Intern Med"},{"key":"key2025031922413200_ref2-bib2","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"key2025031922413200_ref3-bib3","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1046\/j.1523-1755.2003.00109.x","article-title":"Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC study","volume":"64","author":"Abramson","year":"2003","journal-title":"Kidney Int"},{"key":"key2025031922413200_ref4-bib4","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","article-title":"Prevalence of chronic kidney disease in the United States","volume":"298","author":"Coresh","year":"2007","journal-title":"JAMA"},{"key":"key2025031922413200_ref5-bib5","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Matsushita","year":"2010","journal-title":"Lancet"},{"key":"key2025031922413200_ref6-bib6","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/eurheartj\/ehl455","article-title":"The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years","volume":"28","author":"Van Biesen","year":"2007","journal-title":"Eur Heart J"},{"key":"key2025031922413200_ref7-bib7","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa043161","article-title":"Cystatin C and the risk of death and cardiovascular events among elderly persons","volume":"352","author":"Shlipak","year":"2005","journal-title":"N Engl J Med"},{"key":"key2025031922413200_ref8-bib8","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1681\/ASN.2005101085","article-title":"Chronic kidney disease and mortality risk: a systematic review","volume":"17","author":"Tonelli","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"key2025031922413200_ref9-bib9","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1046\/j.1523-1755.64.s87.5.x","article-title":"Chronic kidney disease and cardiovascular disease in the Medicare population","author":"Collins","year":"2003","journal-title":"Kidney Int Suppl"},{"key":"key2025031922413200_ref10-bib10","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2215\/CJN.07761109","article-title":"Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease","volume":"5","author":"Foley","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"key2025031922413200_ref11-bib11","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1681\/ASN.2004030203","article-title":"Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999","volume":"16","author":"Foley","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"key2025031922413200_ref12-bib12","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/ncpneph1004","article-title":"Renal aspirin: will all patients with chronic kidney disease one day take spironolactone?","volume":"5","author":"Bomback","year":"2009","journal-title":"Nat Clin Pract Nephrol"},{"key":"key2025031922413200_ref13-bib13","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease study 2017","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","journal-title":"Lancet"},{"key":"key2025031922413200_ref14-bib14","doi-asserted-by":"crossref","first-page":"e0158765","DOI":"10.1371\/journal.pone.0158765","article-title":"Global prevalence of chronic kidney disease \u2013 a systematic review and meta-analysis","volume":"11","author":"Hill","year":"2016","journal-title":"PLOS ONE"},{"key":"key2025031922413200_ref15-bib15","doi-asserted-by":"crossref","first-page":"c213","DOI":"10.1159\/000320341","article-title":"Creatinine fluctuation has a greater effect than the formula to estimate glomerular filtration rate on the prevalence of chronic kidney disease","volume":"117","author":"de Lusignan","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"key2025031922413200_ref16-bib16","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"key":"key2025031922413200_ref17-bib17","first-page":"1","article-title":"Kidney disease: improving global outcomes (KDIGO). CKD work group 2012: clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"Supplement 3","author":"KDIGO","year":"2013","journal-title":"Kidney Int"},{"key":"key2025031922413200_ref18-bib18","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"key2025031922413200_ref19-bib19","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1136\/bmj.39001.657755.BE","article-title":"Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey","volume":"333","author":"Hallan","year":"2006","journal-title":"BMJ"},{"key":"key2025031922413200_ref20-bib20","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"key2025031922413200_ref21-bib21","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1053\/j.ajkd.2010.02.337","article-title":"Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions","volume":"55","author":"Levey","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"key2025031922413200_ref22-bib22","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1373\/clinchem.2017.276683","article-title":"Systematic review and metaanalysis comparing the bias and accuracy of the modification of diet in renal disease and chronic kidney disease epidemiology collaboration equations in community-based populations","volume":"64","author":"McFadden","year":"2018","journal-title":"Clin Chem"},{"key":"key2025031922413200_ref23-bib23","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.ajkd.2010.03.026","article-title":"Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) study equations for estimating GFR levels above 60\u2009mL\/minute\/1.73 m2","volume":"56","author":"Stevens","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"key2025031922413200_ref24-bib24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1053\/j.ajkd.2010.02.344","article-title":"Modification of the CKD Epidemiology Collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates","volume":"56","author":"Horio","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"key2025031922413200_ref25-bib25","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1053\/j.ajkd.2010.03.008","article-title":"Performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) study equations in healthy South Brazilians","volume":"55","author":"Soares","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"key2025031922413200_ref26-bib26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1471-2296-11-49","article-title":"Predicting the risk of chronic kidney disease in men and women in England and Wales: prospective derivation and external validation of the QKidney Scores","volume":"11","author":"Hippisley-Cox","year":"2010","journal-title":"BMC Fam Pract"},{"key":"key2025031922413200_ref27-bib27","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ahj.2009.06.031","article-title":"Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study","volume":"158","author":"Watanabe","year":"2009","journal-title":"Am Heart J"},{"key":"key2025031922413200_ref28-bib28","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1053\/j.ajkd.2009.12.016","article-title":"Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD study equation for estimated GFR: the atherosclerosis risk in communities (ARIC) study","volume":"55","author":"Matsushita","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"key2025031922413200_ref29-bib29","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/MNH.0b013e32833893e2","article-title":"Advances in glomerular filtration rate-estimating equations","volume":"19","author":"Stevens","year":"2010","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"key2025031922413200_ref30-bib30","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1471-2369-13-42","article-title":"Comparing the association of GFR estimated by the CKD-EPI and MDRD study equations and mortality: the third national health and nutrition examination survey (NHANES III)","volume":"13","author":"Shafi","year":"2012","journal-title":"BMC Nephrol"},{"key":"key2025031922413200_ref32-bib32","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1001\/jama.2015.0602","article-title":"Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review","volume":"313","author":"Levey","year":"2015","journal-title":"JAMA"},{"key":"key2025031922413200_ref33-bib33","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1053\/j.ajkd.2009.11.005","article-title":"A software upgrade: CKD testing in 2010","volume":"55","author":"Becker","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"key2025031922413200_ref34-bib34","doi-asserted-by":"crossref","first-page":"310","DOI":"10.7326\/0003-4819-154-5-201103010-00005","article-title":"Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk: a cohort study","volume":"154","author":"Clase","year":"2011","journal-title":"Ann Intern Med"},{"key":"key2025031922413200_ref35-bib35","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"key":"key2025031922413200_ref36-bib36","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0140-6736(12)61272-0","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis","volume":"380","author":"Mahmoodi","year":"2012","journal-title":"Lancet"},{"key":"key2025031922413200_ref37-bib37","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S2213-8587(15)00040-6","article-title":"Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data","volume":"3","author":"Matsushita","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key2025031922413200_ref38-bib38","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","article-title":"Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention","volume":"108","author":"Sarnak","year":"2003","journal-title":"Circulation"},{"key":"key2025031922413200_ref39-bib39","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.ajkd.2018.02.363","article-title":"Evolution of echocardiographic measures of cardiac disease from CKD to ESRD and risk of all-cause mortality: findings from the CRIC study","volume":"72","author":"Bansal","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"key2025031922413200_ref40-bib40","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/ckj\/sfz095","article-title":"Association of non-invasive measures of subclinical atherosclerosis and arterial stiffness with mortality and major cardiovascular events in chronic kidney disease: systematic review and meta-analysis of cohort studies","volume":"13","author":"Kouis","year":"2020","journal-title":"Clin Kidney J"},{"key":"key2025031922413200_ref41-bib41","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.3390\/ijms20184634","article-title":"FGF23-mediated activation of local RAAS promotes cardiac hypertrophy and fibrosis","volume":"20","author":"B\u00f6ckmann","year":"2019","journal-title":"Int J Mol Sci"},{"key":"key2025031922413200_ref42-bib42","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","article-title":"Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease","volume":"119","author":"Guti\u00e9rrez","year":"2009","journal-title":"Circulation"},{"key":"key2025031922413200_ref43-bib43","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","article-title":"Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease","volume":"79","author":"Isakova","year":"2011","journal-title":"Kidney Int"},{"key":"key2025031922413200_ref44-bib44","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3390\/ijms22010408","article-title":"Fibrosis in chronic kidney disease: pathogenesis and consequences","volume":"22","author":"Panizo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"key2025031922413200_ref45-bib45","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/hrt.2009.184879","article-title":"Arterial stiffness in chronic kidney disease: causes and consequences","volume":"96","author":"Chue","year":"2010","journal-title":"Heart"},{"key":"key2025031922413200_ref46-bib46","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/0886022X.2019.1595646","article-title":"Prevalence of coronary artery calcification and its association with mortality, cardiovascular events in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"41","author":"Wang","year":"2019","journal-title":"Ren Fail"},{"key":"key2025031922413200_ref47-bib47","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1001\/jamacardio.2017.0363","article-title":"Coronary artery calcification and risk of cardiovascular disease and death among patients with chronic kidney disease","volume":"2","author":"Chen","year":"2017","journal-title":"JAMA Cardiol"},{"key":"key2025031922413200_ref48-bib48","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1161\/ATVBAHA.116.306717","article-title":"Medial arterial calcification","volume":"36","author":"Ho","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key2025031922413200_ref49-bib49","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1053\/j.ajkd.2003.12.005","article-title":"Vascular calcification in chronic kidney disease","volume":"43","author":"Goodman","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"key2025031922413200_ref50-bib50","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1161\/01.CIR.103.7.987","article-title":"Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure","volume":"103","author":"Guerin","year":"2001","journal-title":"Circulation"},{"key":"key2025031922413200_ref51-bib51","doi-asserted-by":"crossref","first-page":"9036450","DOI":"10.1155\/2017\/9036450","article-title":"Chronic kidney disease and disproportionally increased cardiovascular damage: does oxidative stress explain the burden?","volume":"2017","author":"Duni","year":"2017","journal-title":"Oxid Med Cell Longev"},{"key":"key2025031922413200_ref52-bib52","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.3390\/jcm9082359","article-title":"Endothelial dysfunction in chronic kidney disease, from biology to clinical outcomes: a 2020 update","volume":"9","author":"Roumeliotis","year":"2020","journal-title":"J Clin Med"},{"key":"key2025031922413200_ref53-bib53","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000485146","article-title":"Arterial stiffness in chronic kidney disease and end-stage renal disease","volume":"45","author":"London","year":"2018","journal-title":"Blood Purif"},{"key":"key2025031922413200_ref54-bib54","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1161\/01.HYP.0000168052.00426.65","article-title":"Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy","volume":"46","author":"O\u2019Rourke","year":"2005","journal-title":"Hypertension"},{"key":"key2025031922413200_ref55-bib55","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1681\/ASN.2004080656","article-title":"Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study","volume":"16","author":"Muntner","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"key2025031922413200_ref56-bib56","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"key2025031922413200_ref57-bib57","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/ki.2011.413","article-title":"The impact of renin\u2013angiotensin\u2013aldosterone system inhibitors on Type 1 and Type 2 diabetic patients with and without early diabetic nephropathy","volume":"81","author":"Hirst","year":"2012","journal-title":"Kidney Int"},{"key":"key2025031922413200_ref58-bib58","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004136.pub2","article-title":"Antihypertensive agents for preventing diabetic kidney disease","author":"Strippoli","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"key2025031922413200_ref59-bib59","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/dom.13648","article-title":"Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis","volume":"21","author":"Toyama","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"key2025031922413200_ref60-bib60","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ahj.2020.10.064","article-title":"Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-systematic review and meta-analysis of randomized placebo-controlled trials","volume":"232","author":"Salah","year":"2021","journal-title":"Am Heart J"},{"key":"key2025031922413200_ref61-bib61","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40262-015-0264-4","article-title":"Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"54","author":"Scheen","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"key2025031922413200_ref62-bib62","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(05)67814-2","article-title":"Effect of inhibitors of the renin\u2013angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis","volume":"366","author":"Casas","year":"2005","journal-title":"Lancet"},{"key":"key2025031922413200_ref63-bib63","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","article-title":"Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study)","volume":"60","author":"Vardeny","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"key2025031922413200_ref64-bib64","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"key2025031922413200_ref65-bib65","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.amjcard.2020.01.009","article-title":"Meta-analysis evaluating the effects of renin\u2013angiotensin\u2013aldosterone system blockade on outcomes of heart failure with preserved ejection fraction","volume":"125","author":"Kuno","year":"2020","journal-title":"Am J Cardiol"},{"key":"key2025031922413200_ref66-bib66","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/clpt.2013.135","article-title":"Renin\u2013angiotensin\u2013aldosterone system inhibitors in heart failure","volume":"94","author":"Shearer","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"key2025031922413200_ref67-bib67","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1210\/en.2010-0465","article-title":"Minireview: aldosterone and mineralocorticoid receptors: past, present, and future","volume":"151","author":"Funder","year":"2010","journal-title":"Endocrinology"},{"key":"key2025031922413200_ref68-bib68","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.pcad.2009.12.003","article-title":"Aldosterone and mineralocorticoid receptors in the cardiovascular system","volume":"52","author":"Funder","year":"2010","journal-title":"Prog Cardiovasc Dis"},{"key":"key2025031922413200_ref69-bib69","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/eurheartj\/ehq019","article-title":"Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study","volume":"31","author":"Tomaschitz","year":"2010","journal-title":"Eur Heart J"},{"key":"key2025031922413200_ref70-bib70","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1161\/01.CIR.0000153800.09920.40","article-title":"Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload","volume":"111","author":"Kuster","year":"2005","journal-title":"Circulation"},{"key":"key2025031922413200_ref71-bib71","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/ajh\/hpy120","article-title":"Mineralocorticoid receptor and cardiovascular disease","volume":"31","author":"Buonafine","year":"2018","journal-title":"Am J Hypertens"},{"key":"key2025031922413200_ref72-bib72","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s11886-020-01399-7","article-title":"Mineralocorticoid receptor antagonists: a comprehensive review of finerenone","volume":"22","author":"Rico-Mesa","year":"2020","journal-title":"Curr Cardiol Rep"},{"key":"key2025031922413200_ref73-bib73","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40620-019-00600-7","article-title":"New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure","volume":"33","author":"Capelli","year":"2020","journal-title":"J Nephrol"},{"key":"key2025031922413200_ref74-bib74","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"key2025031922413200_ref75-bib75","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"key2025031922413200_ref76-bib76","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"key2025031922413200_ref77-bib77","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"key2025031922413200_ref78-bib78","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1161\/01.CIR.0000068340.96506.0F","article-title":"Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction","volume":"107","author":"Hayashi","year":"2003","journal-title":"Circulation"},{"key":"key2025031922413200_ref79-bib79","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ejheart.2004.04.013","article-title":"The clinical implications of aldosterone escape in congestive heart failure","volume":"6","author":"Struthers","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"key2025031922413200_ref80-bib80","article-title":"Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease","volume":"10","author":"Chung","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"key2025031922413200_ref81-bib81","doi-asserted-by":"crossref","first-page":"9995","DOI":"10.3390\/ijms22189995","article-title":"Mineralocorticoid receptor antagonists-use in chronic kidney disease","volume":"22","author":"Baran","year":"2021","journal-title":"Int J Mol Sci"},{"key":"key2025031922413200_ref82-bib82","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1097\/HJH.0000000000002187","article-title":"Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Alexandrou","year":"2019","journal-title":"J Hypertens"},{"key":"key2025031922413200_ref83-bib83","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.amjcard.2010.07.018","article-title":"Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease","volume":"106","author":"Edwards","year":"2010","journal-title":"Am J Cardiol"},{"key":"key2025031922413200_ref84-bib84","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.2215\/CJN.01930221","article-title":"Effects of spironolactone and chlorthalidone on cardiovascular structure and function in chronic kidney disease: a randomized, open-label trial","volume":"16","author":"Edwards","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"key2025031922413200_ref85-bib85","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3390\/jcm7110459","article-title":"Long-term effects of spironolactone on kidney function and hyperkalemia-associated hospitalization in patients with chronic kidney disease","volume":"7","author":"Yang","year":"2018","journal-title":"J Clin Med"},{"key":"key2025031922413200_ref86-bib86","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijcard.2017.03.080","article-title":"Effect of spironolactone on the risks of mortality and hospitalization for heart failure in pre-dialysis advanced chronic kidney disease: a nationwide population-based study","volume":"238","author":"Tseng","year":"2017","journal-title":"Int J Cardiol"},{"key":"key2025031922413200_ref87-bib87","doi-asserted-by":"crossref","first-page":"16626","DOI":"10.1038\/s41598-020-73638-4","article-title":"The effect of aldosterone and aldosterone blockade on the progression of chronic kidney disease: a randomized placebo-controlled clinical trial","volume":"10","author":"Minakuchi","year":"2020","journal-title":"Sci Rep"},{"key":"key2025031922413200_ref88-bib88","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1161\/HYPERTENSIONAHA.120.15199","article-title":"Mineralocorticoid receptor antagonists for hypertension management in advanced chronic kidney disease: BLOCK-CKD trial","volume":"76","author":"Bakris","year":"2020","journal-title":"Hypertension"},{"key":"key2025031922413200_ref89-bib89","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"key2025031922413200_ref90-bib90","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"key2025031922413200_ref91-bib91","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"key2025031922413200_ref92-bib92","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3122\/jabfm.2010.04.090129","article-title":"Chronic kidney disease in primary care","volume":"23","author":"Murphree","year":"2010","journal-title":"J Am Board Fam Med"},{"key":"key2025031922413200_ref93-bib93","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/ndt\/gfm857","article-title":"Primary care-based disease management of chronic kidney disease (CKD), based on estimated glomerular filtration rate (eGFR) reporting, improves patient outcomes","volume":"23","author":"Richards","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"key2025031922413200_ref94-bib94","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/ki.2012.65","article-title":"The implications of anatomical and functional changes of the aging kidney: with an emphasis on the glomeruli","volume":"82","author":"Glassock","year":"2012","journal-title":"Kidney Int"},{"key":"key2025031922413200_ref95-bib95","first-page":"419","article-title":"Ageing and the glomerular filtration rate: truths and consequences","volume":"120","author":"Glassock","year":"2009","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"key2025031922413200_ref96-bib96","doi-asserted-by":"crossref","first-page":"e010519","DOI":"10.1136\/bmjopen-2015-010519","article-title":"Results and lessons from the Spironolactone To Prevent Cardiovascular Events in Early Stage Chronic Kidney Disease (STOP-CKD) randomised controlled trial","volume":"6","author":"Ng","year":"2016","journal-title":"BMJ Open"},{"key":"key2025031922413200_ref97-bib97","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/1745-6215-15-160","article-title":"Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial \u2013 a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25\u2009mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial","volume":"15","author":"Hill","year":"2014","journal-title":"Trials"},{"key":"key2025031922413200_ref98-bib98","volume-title":"National Institute for Health and Care Excellence: Chronic Kidney Disease in Adults: Assessment and Management CG182","author":"NICE","year":"2014"},{"key":"key2025031922413200_ref99-bib99","volume-title":"Clinical Trials for Medicines: Manage Your Authorisation, Report Safety Issues: Gov.UK","author":"Medicines and Healthcare products Regulatory Agency","year":"2014"},{"key":"key2025031922413200_ref100-bib100","doi-asserted-by":"crossref","first-page":"7","DOI":"10.12688\/wellcomeopenres.10005.1","article-title":"A blinded randomised placebo-controlled trial investigating the efficacy of morphine analgesia for procedural pain in infants: trial protocol","volume":"1","author":"Slater","year":"2016","journal-title":"Wellcome Open Res"},{"key":"key2025031922413200_ref101-bib101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-022-06972-9","article-title":"Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial \u2013 a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25\u2009mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial","volume":"23","author":"Hill","year":"2022","journal-title":"Trials"},{"key":"key2025031922413200_ref102-bib102","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11136-011-9927-2","article-title":"Development of a self-report measure of capability wellbeing for adults: the ICECAP-A","volume":"21","author":"Al-Janabi","year":"2012","journal-title":"Qual Life Res"},{"key":"key2025031922413200_ref103-bib103","volume-title":"Visual Analogue Scale \u2013 Quality of Life (VAS QL)","author":"Participation and Quality of Life (PAR-QoL)","year":"2018"},{"key":"key2025031922413200_ref105-bib105","volume-title":"National Cost Collection Data Publication","author":"NHS England","year":"2021"},{"key":"key2025031922413200_ref106-bib106","volume-title":"British National Formulary (BNF)","author":"National Institute for Health and Care Excellence","year":"2022"},{"key":"key2025031922413200_ref107-bib107","volume-title":"Unit Costs of Health and Social Care 2021","author":"Jones","year":"2021"},{"key":"key2025031922413200_ref108-bib108","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"key2025031922413200_ref109-bib109","volume-title":"Policy Research Unit in Economic Evaluation of Health and Care Interventions","author":"Hern\u00e1ndez Alava","year":"2020"},{"key":"key2025031922413200_ref110-bib110","volume-title":"Kidney Disease Quality of Life Short Form (KDQOL-SF\u2122), Version 1.3: A Manual for Use and Scoring","author":"Hays","year":"1997"},{"key":"key2025031922413200_ref111-bib111","volume-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin","year":"2004"},{"key":"key2025031922413200_ref112-bib112","first-page":"1","article-title":"MICE: multivariate imputation by chained equations in R","volume":"45","author":"Van Buuren","year":"2011","journal-title":"J Stat Softw"},{"key":"key2025031922413200_ref113-bib113","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s40273-014-0193-3","article-title":"A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials","volume":"32","author":"Faria","year":"2014","journal-title":"PharmacoEcon"},{"key":"key2025031922413200_ref114-bib114","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/hec.3793","article-title":"A Bayesian framework for health economic evaluation in studies with missing data","volume":"27","author":"Mason","year":"2018","journal-title":"Health Econ"},{"key":"key2025031922413200_ref115-bib115","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: issues and guidance for practice","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"},{"key":"key2025031922413200_ref116-bib116","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1177\/0272989X11418372","article-title":"Developing appropriate methods for cost-effectiveness analysis of cluster randomized trials","volume":"32","author":"Gomes","year":"2012","journal-title":"Med Decis Making"},{"key":"key2025031922413200_ref117-bib117","volume-title":"Econometric Analysis","author":"Greene","year":"2003"},{"key":"key2025031922413200_ref118-bib118","doi-asserted-by":"crossref","DOI":"10.1093\/med\/9780199685028.001.0001","volume-title":"Economic Evaluation in Clinical Trials","author":"Glick","year":"2014"},{"key":"key2025031922413200_ref119-bib119","doi-asserted-by":"crossref","DOI":"10.1201\/9780429246593","volume-title":"An Introduction to the Bootstrap","author":"Efron","year":"1994"},{"key":"key2025031922413200_ref120-bib120","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1002\/sim.7654","article-title":"Bootstrap inference when using multiple imputation","volume":"37","author":"Schomaker","year":"2018","journal-title":"Stat Med"},{"key":"key2025031922413200_ref121-bib121","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/1536867X0400400301","article-title":"Multiple imputation of missing values","volume":"4","author":"Royston","year":"2004","journal-title":"Stata J"},{"key":"key2025031922413200_ref122-bib122","volume-title":"Unit Costs of Health and Social Care 2018","author":"Curtis","year":"2018"},{"key":"key2025031922413200_ref123-bib123","volume-title":"Unit Costs of Health and Social Care 2010","author":"Curtis","year":"2010"},{"key":"key2025031922413200_ref124-bib124","volume-title":"2019\/20 National Cost Collection Data Publication","author":"NHS England","year":"2021"},{"key":"key2025031922413200_ref126-bib126","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial","volume":"15","author":"Ito","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"key2025031922413200_ref127-bib127","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"key2025031922413200_ref128-bib128","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"key2025031922413200_ref129-bib129","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2047349","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/sites\/journalslibrary\/files\/journal_data\/PYFT6977\/PYFT6977.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2047349","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T17:20:15Z","timestamp":1742404815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/PYFT6977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":126,"alternative-id":["10.3310\/PYFT6977"],"URL":"https:\/\/doi.org\/10.3310\/pyft6977","relation":{},"ISSN":["2046-4924"],"issn-type":[{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"09-2012","name":"contractual_start_date","label":"contractual_start_date","group":{"name":"article_history","label":"Article History"}},{"value":"07-2023","name":"editorial_review_begun","label":"editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"03-2024","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}